PanCAN adds FibroGen’s drug as treatment arm to adaptive Precision Promise trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Pancreatic Cancer Action Network has added another treatment arm by biopharmaceutical company FibroGen Inc. to its clinical trial platform, Precision Promise.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login